News
- Author:
- Jim Kling
Publish date: September 27, 2022
Response to treatment may lead to a reduction in potentially disfiguring surgeries.
News
- Author:
- Jim Kling
Publish date: September 26, 2022
The finding underscores the need for nutritional support emphasized in 2020 ASCO guidelines.
News
- Author:
- Jim Kling
Publish date: September 22, 2022
The reasons behind the findings and implications for treatment are unknown, as is whether it applies to patients with specific cancers.
News
- Author:
- Jim Kling
Publish date: September 21, 2022
Early toxicity results are encouraging, but long-term efficacy and safety remain unknown.
News
- Author:
- Jim Kling
Publish date: September 15, 2022
Diagnosis time varied significantly across tumor types, as well as within the same tumor type.
News
- Author:
- Jim Kling
Publish date: September 15, 2022
Despite positive results, immunotherapy likely remains the best choice for first-line treatment of BRAFV600 mutated advanced melanoma.
News
- Author:
- Jim Kling
Publish date: September 14, 2022
Opponents of screening suggested while screening may identify cancer earlier, it doesn’t necessarily improve outcomes.
News
- Author:
- Jim Kling
Publish date: September 14, 2022
Patients with the Ex20 insertion may buck trend by responding well to ICIs.
News
- Author:
- Jim Kling
Publish date: September 14, 2022
Respiratory and cardiometabolic comorbidities were associated with significantly worse overall survival in lung cancer.
News
- Author:
- Jim Kling
Publish date: September 14, 2022
Study hints at mechanistic differences between small cell lung cancer in smokers versus nonsmokers.
News
- Author:
- Jim Kling
Publish date: September 12, 2022
Microbiome-based calibration could improve sensitivity and specificity, which could improve efforts to monitor disease activity.
News
- Author:
- Jim Kling
Publish date: September 9, 2022
New research suggests mechanisms behind how adenosine leads to immunosuppression in the tumor microenvironment.
News
- Author:
- Jim Kling
Publish date: September 1, 2022
Early toxicity results are encouraging, but long-term efficacy and safety remain unknown.
News
- Author:
- Jim Kling
Publish date: August 31, 2022
Authors of a systematic review suggest the combinations should be widely available as first-line treatment.
News
- Author:
- Jim Kling
Publish date: August 29, 2022
The predictive model relies on factors readily available in EHRs and could potentially be automated using e-Trigger tools.
